Literature DB >> 13446371

The treatment of experimental toxoplasmosis in rabbits.

J K BEVERLEY, B A FRY.   

Abstract

Sulphadimidine alone is of little value in treating experimental toxoplasmosis in rabbits, because most rabbits acetylate the drug very rapidly. Within a short time of dosing such animals, there is little or none of the uncombined drug in the blood. In rabbits which do not acetylate sulphadimidine rapidly, relatively high concentrations of the free sulphonamide can be attained in the blood: in such animals, toxoplasmosis responds to treatment with sulphadimidine. Sulphathiazole is not acetylated so rapidly and is effective even in rabbits which acetylate sulphadimidine quickly. Pyrimethamine, even in doses as high as 50 mg. three times daily, is ineffective; dapsone is effective.

Entities:  

Keywords:  ANTIMALARIALS/effects; SULFONAMIDES/effects; SULFONES/effects; TOXOPLASMOSIS/experimental

Mesh:

Substances:

Year:  1957        PMID: 13446371      PMCID: PMC1509661          DOI: 10.1111/j.1476-5381.1957.tb00118.x

Source DB:  PubMed          Journal:  Br J Pharmacol Chemother        ISSN: 0366-0826


  4 in total

1.  Experimental toxoplasmosis of the uveal tract.

Authors:  J K BEVERLEY; C P BEATTIE; B A FRY
Journal:  Br J Ophthalmol       Date:  1954-08       Impact factor: 4.638

2.  The present status of the chemotherapy of toxoplasmosis.

Authors:  D E EYLES
Journal:  Am J Trop Med Hyg       Date:  1953-05       Impact factor: 2.345

3.  Antibacterial action and metabolism of five sulphones.

Authors:  J FRANCIS; A SPINKS
Journal:  Br J Pharmacol Chemother       Date:  1950-12

4.  The effects of oral administration of aureomycin, sulfathiazole, sulfamerazine and 4,4'-diamino diphenyl sulfone on toxoplasmosis in mice.

Authors:  W A SUMMERS
Journal:  Am J Trop Med Hyg       Date:  1949-11       Impact factor: 2.345

  4 in total
  1 in total

Review 1.  Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice.

Authors:  Ildiko Rita Dunay; Kiran Gajurel; Reshika Dhakal; Oliver Liesenfeld; Jose G Montoya
Journal:  Clin Microbiol Rev       Date:  2018-09-12       Impact factor: 26.132

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.